Small intestinal bacterial overgrowth (SIBO) — defined as excess bacteria in the small intestine (>103 CFU/mL by aspirate culture, or positive lactulose/glucose breath test) — has emerged as a significant clinical entity linking gut dysbiosis to irritable bowel syndrome, fibromyalgia, rosacea, and systemic inflammation. However, diagnostic controversies, inconsistent testing protocols, and evolving treatment evidence make SIBO one of the most debated topics in gastroenterology.
Diagnostic Testing: Accuracy and Limitations
Lactulose hydrogen breath test: widely used due to non-invasiveness and accessibility. Sensitivity ~52–68%, specificity 44–84% depending on protocol and cut-off criteria — high false-positive and false-negative rates limit reliability. Glucose hydrogen breath test: higher specificity (~83%) but misses distal SIBO beyond the first 100cm of small intestine. Jejunal aspirate with culture: gold standard but invasive (endoscopy required) and subject to contamination during collection. Key pitfall: many positive breath tests represent accelerated small bowel transit (rapid transit mimics SIBO) rather than true bacterial overgrowth — making clinical correlation essential. The Rome IV criteria now acknowledge the IBS-SIBO overlap but emphasize that SIBO-positive IBS patients respond to rifaximin similarly regardless of breath test result. For lab facilities performing breath testing, our laboratory supplies section includes collection tubes and specimen management products.
Treatment: Rifaximin and Elemental Diet
Rifaximin (Xifaxan): the only FDA-approved treatment for IBS-D, with meta-analysis showing 57% global symptom improvement versus 45% placebo. For SIBO specifically, rifaximin 550mg TID × 14 days achieves 49–87% breath test normalization in trials. Non-absorbable gut-selective antibiotic with low resistance development — preferred over systemic antibiotics. Methane-predominant SIBO (now termed IMO — intestinal methanogen overgrowth): rifaximin alone is insufficient; combination with neomycin or lovastatin-based protocols shows superior methane reduction. Elemental diet (14-day course of amino acid-based formula): 80–85% breath test normalization — highly effective but challenging compliance. Prokinetics (low-dose erythromycin, prucalopride): reduce relapse by promoting small bowel motility between meals.
